JP2024503235A - Ｃｄｋ２阻害剤の固体形態 - Google Patents

Ｃｄｋ２阻害剤の固体形態 Download PDF

Info

Publication number
JP2024503235A
JP2024503235A JP2023537491A JP2023537491A JP2024503235A JP 2024503235 A JP2024503235 A JP 2024503235A JP 2023537491 A JP2023537491 A JP 2023537491A JP 2023537491 A JP2023537491 A JP 2023537491A JP 2024503235 A JP2024503235 A JP 2024503235A
Authority
JP
Japan
Prior art keywords
cancer
ppm
crystalline
values
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503235A5 (enExample
Inventor
カオ フェンジュアン
フランシス ディボイェス ケヴィン
ヘバーライン マイケル
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2024503235A publication Critical patent/JP2024503235A/ja
Publication of JP2024503235A5 publication Critical patent/JP2024503235A5/ja
Priority to JP2026067895A priority Critical patent/JP2026123057A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cereal-Derived Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023537491A 2020-12-24 2021-12-21 Ｃｄｋ２阻害剤の固体形態 Pending JP2024503235A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026067895A JP2026123057A (ja) 2020-12-24 2026-04-16 Ｃｄｋ２阻害剤の固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130530P 2020-12-24 2020-12-24
US63/130,530 2020-12-24
PCT/IB2021/062082 WO2022137106A1 (en) 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026067895A Division JP2026123057A (ja) 2020-12-24 2026-04-16 Ｃｄｋ２阻害剤の固体形態

Publications (2)

Publication Number Publication Date
JP2024503235A true JP2024503235A (ja) 2024-01-25
JP2024503235A5 JP2024503235A5 (enExample) 2024-11-28

Family

ID=79283019

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023537491A Pending JP2024503235A (ja) 2020-12-24 2021-12-21 Ｃｄｋ２阻害剤の固体形態
JP2026067895A Pending JP2026123057A (ja) 2020-12-24 2026-04-16 Ｃｄｋ２阻害剤の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026067895A Pending JP2026123057A (ja) 2020-12-24 2026-04-16 Ｃｄｋ２阻害剤の固体形態

Country Status (10)

Country Link
US (1) US20240076287A1 (enExample)
EP (1) EP4267563A1 (enExample)
JP (2) JP2024503235A (enExample)
KR (1) KR20230122100A (enExample)
CN (1) CN116723837B (enExample)
AU (1) AU2021404974B2 (enExample)
CA (1) CA3206153A1 (enExample)
MX (1) MX2023007699A (enExample)
TW (1) TWI823213B (enExample)
WO (1) WO2022137106A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
CN118679150A (zh) * 2022-01-27 2024-09-20 益方生物科技(上海)股份有限公司 Cdk2抑制剂及其制备方法和用途
WO2024046443A1 (en) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Macrocyclic compounds as selective cdk inhibitors
WO2025191482A1 (en) 2024-03-15 2025-09-18 Pfizer Inc. Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005773392 *
厚生省医薬安全局審査管理課長: "医薬品の残留溶媒ガイドラインについて", 医薬審, JPN6014031669, 1998, ISSN: 0005773390 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005773389 *
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005773391 *

Also Published As

Publication number Publication date
MX2023007699A (es) 2023-07-10
KR20230122100A (ko) 2023-08-22
TW202233606A (zh) 2022-09-01
AU2021404974A1 (en) 2023-07-06
JP2026123057A (ja) 2026-07-29
AU2021404974B2 (en) 2024-11-28
WO2022137106A1 (en) 2022-06-30
TWI823213B (zh) 2023-11-21
EP4267563A1 (en) 2023-11-01
CN116723837B (zh) 2026-05-26
CN116723837A (zh) 2023-09-08
CA3206153A1 (en) 2022-06-30
AU2021404974A9 (en) 2025-04-10
US20240076287A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
JP7291839B2 (ja) 固体形態のｃｄｋ４阻害薬
TWI823213B (zh) Cdk2抑制劑之固體形式
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
KR20230121756A (ko) Fgfr 억제제 및 이의 제조 및 사용 방법
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
CN117337293A (zh) 固体形式的eif4e抑制剂
ES3032458T3 (en) Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
CN118678958A (zh) 药物组合物及其用途
JP2025540560A (ja) Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
RU2850825C1 (ru) Твердые формы ингибитора cdk2
CA3195063C (en) Solid forms of the cdk4 inhibitor pf-07220060
RU2856216C1 (ru) Твердые формы ингибитора cdk4
HK40096368A (en) Solid forms of a cdk2 inhibitor
BR112023004713B1 (pt) Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica
HK40087859A (en) Solid forms of a cdk4 inhibitor
EP3389660B1 (en) Combination therapy for cancer
HK40131055A (en) A pharmaceutical combination and use thereof
HK40125945A (en) Fumarate, tartrate, malate, and citrate salts of an egfr inhibitor
EA049394B1 (ru) Ингибиторы fgfr и способы их получения и применения
HK40066730A (en) Treatment of cancers having driving oncogenic mutations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260119